Opdualag Európai Unió - magyar - EMA (European Medicines Agency)

opdualag

bristol-myers squibb pharma eeig - nivolumab, relatlimab - melanóma - antineoplastic agents, monoclonal antibodies - opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell pd l1 expression < 1%.

Sotyktu Európai Unió - magyar - EMA (European Medicines Agency)

sotyktu

bristol-myers squibb pharma eeig - deucravacitinib - pikkelysömör - immunszuppresszánsok - treatment of moderate-to-severe plaque psoriasis in adults.